Literature DB >> 28778794

Vitiligo: Mechanistic insights lead to novel treatments.

Michael L Frisoli1, John E Harris2.   

Abstract

Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting melanocyte regeneration. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies and their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCL10; CXCL9; CXCR3; IFN-γ; NLRP1; NLRP3; T cell; Vitiligo; clinical trials; hair; inflammasome; innate immunity; melanocyte; regeneration; regulation; repigmentation; resident memory; stress; treatment

Mesh:

Substances:

Year:  2017        PMID: 28778794     DOI: 10.1016/j.jaci.2017.07.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  27 in total

Review 1.  Insights into the role of endoplasmic reticulum stress in skin function and associated diseases.

Authors:  Kyungho Park; Sang Eun Lee; Kyong-Oh Shin; Yoshikazu Uchida
Journal:  FEBS J       Date:  2019-01       Impact factor: 5.542

Review 2.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

Review 3.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

Review 4.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

5.  scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function.

Authors:  Kyle J Gellatly; James P Strassner; Kingsley Essien; Maggi Ahmed Refat; Rachel L Murphy; Anthony Coffin-Schmitt; Amit G Pandya; Andrea Tovar-Garza; Michael L Frisoli; Xueli Fan; Xiaolan Ding; Evangeline E Kim; Zainab Abbas; Patrick McDonel; Manuel Garber; John E Harris
Journal:  Sci Transl Med       Date:  2021-09-08       Impact factor: 17.956

6.  Association of Clinical Markers With Disease Progression in Patients With Vitiligo From China.

Authors:  Li Zhang; Shujun Chen; Yuli Kang; Xiuxiu Wang; Fang Yan; Min Jiang; Qianqian Wang; Ziqi Liu; Chengfeng Zhang; Leihong Xiang
Journal:  JAMA Dermatol       Date:  2020-03-01       Impact factor: 10.282

7.  Mouse Model for Human Vitiligo.

Authors:  Rebecca L Riding; Jillian M Richmond; John E Harris
Journal:  Curr Protoc Immunol       Date:  2018-09-25

Review 8.  T cells and the skin: from protective immunity to inflammatory skin disorders.

Authors:  Allen W Ho; Thomas S Kupper
Journal:  Nat Rev Immunol       Date:  2019-08       Impact factor: 53.106

9.  Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Mehdi Rashighi; Priti Agarwal; Madhuri Garg; Kingsley I Essien; Lila S Pell; John E Harris
Journal:  J Invest Dermatol       Date:  2018-11-10       Impact factor: 8.551

Review 10.  Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-20       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.